Annual EBIT
-$72.21 M
-$15.76 M-27.92%
September 30, 2024
Summary
- As of February 22, 2025, OTLK annual earnings before interest & taxes is -$72.21 million, with the most recent change of -$15.76 million (-27.92%) on September 30, 2024.
- During the last 3 years, OTLK annual EBIT has fallen by -$19.98 million (-38.26%).
- OTLK annual EBIT is now -482.67% below its all-time high of -$12.39 million, reached on September 30, 2014.
Performance
OTLK EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$21.61 M
-$27.30 M-479.65%
December 31, 2024
Summary
- As of February 22, 2025, OTLK quarterly earnings before interest & taxes is -$21.61 million, with the most recent change of -$27.30 million (-479.65%) on December 31, 2024.
- Over the past year, OTLK quarterly EBIT has dropped by -$27.30 million (-479.65%).
- OTLK quarterly EBIT is now -148.65% below its all-time high of $44.41 million, reached on June 30, 2024.
Performance
OTLK Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
$9.55 M
-$11.28 M-54.15%
December 31, 2024
Summary
- As of February 22, 2025, OTLK TTM earnings before interest & taxes is $9.55 million, with the most recent change of -$11.28 million (-54.15%) on December 31, 2024.
- Over the past year, OTLK TTM EBIT has dropped by -$11.28 million (-54.15%).
- OTLK TTM EBIT is now -54.15% below its all-time high of $20.84 million, reached on September 30, 2024.
Performance
OTLK TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
OTLK EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -27.9% | -479.6% | -54.1% |
| 3 y3 years | -38.3% | -26.9% | +115.1% |
| 5 y5 years | -109.5% | -331.8% | +125.4% |
OTLK EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -38.3% | at low | -148.7% | at low | -54.1% | +114.2% |
| 5 y | 5-year | -109.5% | at low | -148.7% | at low | -54.1% | +114.2% |
| alltime | all time | -482.7% | at low | -148.7% | +1.9% | -54.1% | +114.2% |
Outlook Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$21.61 M(-479.6%) | $9.55 M(-54.2%) |
| Sep 2024 | -$72.21 M(+27.9%) | $5.69 M(-87.2%) | $20.84 M(+866.7%) |
| Jun 2024 | - | $44.41 M(-334.5%) | $2.16 M(-103.4%) |
| Mar 2024 | - | -$18.94 M(+83.5%) | -$62.93 M(+23.8%) |
| Dec 2023 | - | -$10.32 M(-20.5%) | -$50.83 M(-9.5%) |
| Sep 2023 | -$56.45 M(-12.6%) | -$12.99 M(-37.2%) | -$56.19 M(-4.2%) |
| Jun 2023 | - | -$20.67 M(+202.4%) | -$58.68 M(+6.6%) |
| Mar 2023 | - | -$6.84 M(-56.4%) | -$55.03 M(-18.0%) |
| Dec 2022 | - | -$15.69 M(+1.4%) | -$67.10 M(+2.4%) |
| Sep 2022 | -$64.56 M(+23.6%) | -$15.48 M(-9.1%) | -$65.52 M(+3.7%) |
| Jun 2022 | - | -$17.02 M(-10.0%) | -$63.18 M(+8.8%) |
| Mar 2022 | - | -$18.91 M(+34.0%) | -$58.10 M(+11.6%) |
| Dec 2021 | - | -$14.11 M(+7.4%) | -$52.04 M(-0.4%) |
| Sep 2021 | -$52.23 M(+42.1%) | -$13.14 M(+10.0%) | -$52.23 M(+6.6%) |
| Jun 2021 | - | -$11.94 M(-7.1%) | -$48.99 M(+14.2%) |
| Mar 2021 | - | -$12.85 M(-10.1%) | -$42.90 M(+22.4%) |
| Dec 2020 | - | -$14.30 M(+44.4%) | -$35.05 M(-4.6%) |
| Sep 2020 | -$36.76 M(+6.6%) | -$9.90 M(+69.5%) | -$36.76 M(-6.6%) |
| Jun 2020 | - | -$5.84 M(+16.8%) | -$39.37 M(+4.5%) |
| Mar 2020 | - | -$5.00 M(-68.7%) | -$37.67 M(-10.0%) |
| Dec 2019 | - | -$16.01 M(+27.8%) | -$41.85 M(+21.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | -$34.47 M(+15.5%) | -$12.52 M(+202.7%) | -$34.47 M(+2.8%) |
| Jun 2019 | - | -$4.14 M(-55.0%) | -$33.54 M(-8.6%) |
| Mar 2019 | - | -$9.19 M(+6.6%) | -$36.69 M(+7.5%) |
| Dec 2018 | - | -$8.62 M(-25.6%) | -$34.12 M(+14.3%) |
| Sep 2018 | -$29.85 M(-8.8%) | -$11.59 M(+59.1%) | -$29.85 M(+35.8%) |
| Jun 2018 | - | -$7.28 M(+10.1%) | -$21.99 M(+20.2%) |
| Mar 2018 | - | -$6.62 M(+52.0%) | -$18.29 M(-1.0%) |
| Dec 2017 | - | -$4.35 M(+16.8%) | -$18.47 M(-43.6%) |
| Sep 2017 | -$32.72 M(-36.3%) | -$3.73 M(+4.0%) | -$32.72 M(-16.0%) |
| Jun 2017 | - | -$3.59 M(-47.3%) | -$38.95 M(-32.1%) |
| Mar 2017 | - | -$6.80 M(-63.4%) | -$57.39 M(+7.2%) |
| Dec 2016 | - | -$18.61 M(+86.9%) | -$53.54 M(+4.3%) |
| Sep 2016 | -$51.35 M(+10.3%) | -$9.95 M(-54.8%) | -$51.35 M(-12.6%) |
| Jun 2016 | - | -$22.03 M(+645.7%) | -$58.77 M(+23.0%) |
| Mar 2016 | - | -$2.95 M(-82.0%) | -$47.78 M(-18.8%) |
| Dec 2015 | - | -$16.41 M(-5.5%) | -$58.83 M(+26.4%) |
| Sep 2015 | -$46.56 M(+275.7%) | -$17.37 M(+57.3%) | -$46.56 M(+59.5%) |
| Jun 2015 | - | -$11.05 M(-21.1%) | -$29.19 M(+60.9%) |
| Mar 2015 | - | -$14.00 M(+237.9%) | -$18.14 M(+337.9%) |
| Dec 2014 | - | -$4.14 M | -$4.14 M |
| Sep 2014 | -$12.39 M | - | - |
FAQ
- What is Outlook Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Outlook Therapeutics?
- What is Outlook Therapeutics annual EBIT year-on-year change?
- What is Outlook Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly EBIT year-on-year change?
- What is Outlook Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Outlook Therapeutics?
- What is Outlook Therapeutics TTM EBIT year-on-year change?
What is Outlook Therapeutics annual earnings before interest & taxes?
The current annual EBIT of OTLK is -$72.21 M
What is the all time high annual EBIT for Outlook Therapeutics?
Outlook Therapeutics all-time high annual earnings before interest & taxes is -$12.39 M
What is Outlook Therapeutics annual EBIT year-on-year change?
Over the past year, OTLK annual earnings before interest & taxes has changed by -$15.76 M (-27.92%)
What is Outlook Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of OTLK is -$21.61 M
What is the all time high quarterly EBIT for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly earnings before interest & taxes is $44.41 M
What is Outlook Therapeutics quarterly EBIT year-on-year change?
Over the past year, OTLK quarterly earnings before interest & taxes has changed by -$27.30 M (-479.65%)
What is Outlook Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of OTLK is $9.55 M
What is the all time high TTM EBIT for Outlook Therapeutics?
Outlook Therapeutics all-time high TTM earnings before interest & taxes is $20.84 M
What is Outlook Therapeutics TTM EBIT year-on-year change?
Over the past year, OTLK TTM earnings before interest & taxes has changed by -$11.28 M (-54.15%)